BioVie Announces Additional Findings from Phase II Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

By
Jamie Kang
-
0
147
BioVie Inc. announced encouraging data suggesting that NE3107 had an impact on improving patients’ DNA methylation profiles, potentially impacting biomarkers of aging-related disease states.
[BioVie, Inc.]
Press Release